Business Context and Reporting Period
TransMedics Group, Inc. filed this Form 8-K regarding its 2024 Annual Meeting of Shareholders, held May 23, 2024. The report was signed May 28, 2024. The company is incorporated in Massachusetts and its common stock trades on Nasdaq under the symbol TMDX.
Financial Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.
Material Changes and Voting Results
- Board election: All eight director nominees were elected to serve until the 2025 annual meeting or until their successors are elected and qualified.
- Executive compensation: Shareholders approved, on a non-binding advisory basis, the compensation paid to the company’s named executive officers: 22,902,359 for, 1,321,627 against, 16,949 abstentions, and 2,988,846 broker non-votes.
- Auditor ratification: Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024: 26,468,778 for, 748,890 against, and 12,113 abstentions.
Director Vote Results
| Nominee | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Waleed Hassanein, M.D. | 24,024,298 | 208,947 | 7,690 | 2,988,846 |
| James R. Tobin | 23,518,088 | 711,239 | 11,608 | 2,988,846 |
| Edward M. Basile | 19,849,603 | 4,379,664 | 11,668 | 2,988,846 |
| Thomas J. Gunderson | 23,873,171 | 356,023 | 11,741 | 2,988,846 |
| Edwin M. Kania, Jr. | 23,550,271 | 679,023 | 11,641 | 2,988,846 |
| Stephanie Lovell | 23,789,019 | 441,905 | 10,011 | 2,988,846 |
| Merilee Raines | 23,928,824 | 302,040 | 10,071 | 2,988,846 |
| David Weill, M.D. | 23,735,272 | 494,175 | 11,488 | 2,988,846 |
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance, operational outlook, management commentary, risk updates, contingencies, or unusual items beyond the reported shareholder votes.
Facts to Verify
- Confirm the continued service of all eight elected directors through the 2025 annual meeting, subject to earlier changes permitted by the company’s governing documents.
- Review subsequent filings for any actions or changes related to the advisory executive compensation vote.
- Confirm that PricewaterhouseCoopers LLP remains the company’s independent auditor for fiscal 2024.
- Use the company’s periodic financial filings for current revenue, profitability, cash flow, debt, liquidity, and outlook information, which are not included here.